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Abstract
Background: Tuberculosis (TB) patients in China encounter heavy financial burdens throughout the course of their
treatment and it is unclear how China’s health insurance systems affect the alleviation of this burden under the
integrated approach. This study aimed to measure reimbursement for TB services under the New Cooperative
Medical Scheme (NCMS) in rural China and to evaluate changes in catastrophic health expenditure (CHE) caused by
the reimbursement policies.
Methods: Reimbursement data were obtained from routine data systems for the NCMS in Yichang (YC) and
Hanzhong (HZ). 1884 TB inpatients reimbursed by NCMS from 2010 to 2012 were included. Household surveys
were conducted. A total of 494 TB patients under the NCMS were selected in this paper. 12 Focus Group
Discussions (FGDs) were held. We measured the impact of the NCMS by counterfactual analysis, which analyzed the
financial burden alleviation. Equity was assessed by Concentration Index (CI), and disaggregated by project sites.
Results: TB inpatients were reimbursed with an effective reimbursement rate of 57.3 %. Average out-of-pocket
(OOP) payments for outpatient and inpatient services after diagnosis were 1413 yuan and 430 yuan, and 3572 yuan
and 3013 yuan in YC and HZ, respectively. The reimbursement level for TB outpatient care after diagnosis was very
low due to a limited outpatient quota. TB patients in HZ incurred higher effective reimbursement rates, but the
incidence of CHE remained higher. The reduction of CHE incidence after the NCMS showed no difference
statistically (P > 0.05). The severity of CHE was alleviated slightly. CIs after reimbursement were all below zero and
their absolute values were higher than those before reimbursement.
Conclusions: Low reimbursement for TB patients could lead to heavy financial burden. Poor TB patients incurred
high rates of CHE. The NCMS was found to be a protective factor for CHE, but the impact was modest and the
equity of CHE did not improve. The NCMS reimbursement policies should be improved in the future to include a
more comprehensive coverage of care. Supplemental programs may be necessary to expand coverage for TB care.
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Background
China has the second largest burden of tuberculosis (TB)
in the world [1], and the “directly observed treatment
short course” (DOTS) has been implemented by China’s
National TB Program to combat this problem. One smear
microscopy and one radiography at first visit, and drugs
(6 months for new patients, 8 months if previously
treated) are provided free of charge. Despite this, TB pa-
tients frequently encounter high costs, often through add-
itional medicines, X-rays and laboratory services, during
the course of their treatment [2–4]. Within the current
TB control program, two main approaches have been
employed in China: the TB dispensary approach and the
integrated approach [5]. In the TB dispensary approach,
TB dispensaries [usually departments of the Center for
Diseases Control (CDC)] are in charge of TB case detec-
tion, diagnosis, treatment, and case management. TB sus-
pects and patients should be reported and referred to TB
dispensaries to confirm diagnoses and for treatment by
health workers in general hospitals. Only severe or com-
plicated TB cases are further treated in general hospitals.
Since 2000, TB prevention and treatment services have
transformed from TB dispensaries to designated hospitals
in what is called the integrated approach. This design al-
lows TB dispensaries to provide public health care and
general hospitals to offer integrated care to TB patients
without referral. Other hospitals, including township hos-
pitals, are responsible for referring suspects and patients
to the designated hospitals. The integrated model has
been considered the better policy option for future TB
health reform in China [6]. Prior studies have shown that
TB poses a heavy financial burden on patients, especially
on those in rural areas [7]. A systematic review conducted
in low- and middle-income countries has shown that cost
as a percentage of income was particularly high among
poor people [8]. With the considerable strain that TB
places on its population, protecting TB patients from fi-
nancial risk is a priority for Chinese policymakers.
Social protection mechanisms were highlighted in the
post-2015 Global TB Strategy put forward by The World
Health Organization. Health insurance has been considered
as a promising way to protect people from financial catas-
trophe and impoverishment [9–11]. As for TB control, in
the United States, ongoing efforts to control TB were
enhanced by bringing millions of currently uninsured
Americans into the health care system [12]. Integrating the
national TB control program into health insurance schemes
is an effective strategy to address challenges in current
China [13]. Lack of health insurance is reported to be the
key determinant of insufficient TB control in many ways.
According to one prospective cohort study, having health
insurance helped to improve latent tuberculous infection
treatment completion rates in the United States and
Canada [14], while a lack of health insurance was found to
be responsible for delay in seeking TB care in China [15].
In rural China, TB patients are reimbursed by the New
Cooperative Medical Scheme (NCMS). There is a growing
body of literature that evaluates the impacts of the NCMS
programs on health care utilization and economic burden
[16–20]; however, they mainly focus on the variation of
financial burden on the whole population before and after
the NCMS, and few target the impacts of different NCMS
reimbursement policies on TB patients specifically. A re-
cent study accessed the effective reimbursement rates of
the NCMS among TB patients [21], but it compared TB
patients who lived in counties where their schemes covered
costs within TB dispensaries and those who did not. None-
theless, the alleviation of financial burden among TB pa-
tients during the entire course of treatment under the
integrated approach remains unknown. Moreover, more in-
dicators are needed to assess the impacts of the NCMS on
financial burden.
TB patients have several distinctive features in their
demand for health care. First, from the clinical view-
point, only a small proportion of TB patients require
treatment via inpatient services. More commonly, TB
patients need repeated, long-term outpatient visits.
Second, under the current health care system in China,
primary care physicians practicing in local clinics or
public health centers often do not have the capacity to
treat TB patients due to resource and educational con-
straints. Rather, TB patients are treated at county- or
city-level hospitals based on the national TB control pol-
icies in China. While the NCMS may be beneficial to
meet the unmet health care needs of those in rural
China [22], under the integrated approach, its impact on
alleviating the financial burden on TB patients in rural
populations using diversified indexes and whether this
impact is consistent with that of the whole population
has yet to be unveiled.
This study focused on TB patients in rural areas of
central and western China. We measured TB care reim-
bursement under the NCMS by using data from patient
surveys and the NCMS database. We then assessed the
impacts of the NCMS on the financial burden of TB pa-
tients by counterfactual analysis and discussed whether
the NCMS reimbursement policy reached the goal of
equity by using the CI.
Methods
Study setting
The national TB epidemiology survey in 2010 revealed
that there existed significant differences in the prevalence
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of active pulmonary TB across different regions in China.
The prevalence of active pulmonary TB in the western
region was about 1.7 times that in the central region, and
2.4 times that in the eastern region. Moreover, the preva-
lence of active pulmonary TB in rural areas was about 1.6
times that in urban areas. Hence, this paper focuses on TB
care reimbursement in rural areas of central and western
China.
The China National Health and Family Planning
Commission (NHFPC)-Bill & Melinda Gates Founda-
tion TB Project has been widely conducted in Yichang
(YC) and Hanzhong (HZ). The local governments were
able and willing to collaborate in this study. The study
was therefore conducted in these two cities.
YC is located in the more developed area of central
China and had a GDP per capita of 73,947 yuan in 2011.
By contrast, HZ is a relatively low-income area located
in western China, which had a GDP per capita of 16,935
yuan in 2011. YC and HZ adopted the integrated ap-
proach. Therefore, TB dispensaries were responsible for
TB control planning, case reporting, drug procurement
and distribution, defaults tracing and health education.
One county-level general hospital was designated for in-
tegrated care within one county.
Three counties (one from each category of high, mid-
dle and low GDP per capita) were purposively selected
in each city. As a result, we chose six counties as our
study settings: Yidu (YD), Zhijiang (ZJ) and Wufeng
(WF) in YC and Chenggu (CG), Mianxian (MX) and
Zhenba (ZB) in HZ.
Data collection
Data collection employed a combination of both quanti-
tative and qualitative methods. Quantitative data pro-
vided intuitional phenomenon, and qualitative data
helped to gain a deeper and more complete understand-
ing of the situation. Quantitative studies included TB
patient surveys and reimbursement data from the exist-
ing routine data systems for the NCMS. Qualitative
studies mainly consisted of a number of Focus Group
Discussions (FGDs) and policy documents.
Quantitative study
We adopted probability proportional to size (PPS) sam-
pling to select TB patients. Through this process, we
planned to obtain 270 cases per city. Thus, 90 cases per
county were needed.
First, townships were randomly selected in each
county. We planned to select six townships according to
the previous TB case registration list. In ZJ, for example,
370 TB cases were registered in 2012. The sampling
interval was 61, and the random number was 29. Ac-
cordingly, we listed the sampled patients in a table and
the sampled townships were chosen.
Second, 15 TB cases – patients who had completed or
stopped treatment during 2012 – were selected in each
of the six townships from the TB case registration list. If
the sample size of the sampled township was not
enough, we supplemented it by choosing from a nearby
township. If the sample size was still not enough in this
situation, we chose patients who registered in the latter
half of 2011 and completed the treatment course.
A standardized questionnaire was designed to conduct
patient surveys by face-to-face interviews at local
dispensaries or designated hospitals. We collected add-
itional information on personal demographic and socio-
economic status (such as education, household income/
expenditure), TB related diagnostic and treatment path-
way, direct health service expenditures, and on the reim-
bursements from health insurance. The patient survey
was conducted by university students from local cities
and provinces. These students received training on inter-
view skills and the contents of the questionnaire. Since
this paper focuses on patients with health insurance
coverage under the NCMS program, we excluded TB
patients with other forms of health insurance schemes.
As a result, we had 494 patients in our final sample.
In order to understand the medical costs and reim-
bursements of TB patients, we collected reimbursement
data from January 2010 to December 2012 from the
existing NCMS routine data system in each of the six
counties. Eligible patients were identified via a TB diag-
nosis code from the information system. The reimburse-
ment data contained information on the patient’s name,
sex, age group, choice of health providers, hospitalization
costs, and the reimbursement expenses.
In sum, quantitative data were collected from the TB
patient database and the NCMS database. These two da-
tabases were complementary. On one hand, due to recall
bias, TB patients may have exaggerated their medical ex-
penses to highlight their economic burden and they were
only able to remember their out-of-pocket (OOP) pay-
ments. The NCMS database, however, provided rela-
tively accurate data about total and reimbursement
expenses. On the other hand, medical expenditures be-
yond the NCMS reimbursement packages may have
been excluded by the NCMS managers to report higher
reimbursement rates for their counties. By comparing
expenditures and reimbursement rates with the patient
database, we were able to gain more detailed informa-
tion. For these reasons, the effective reimbursement
rates from the patient database were lower than those
from medical expense records.
Qualitative study
FGDs were held with health care providers from the des-
ignated hospitals and TB patients. There were 6 groups
each in both YC and HZ. Participants were selected with
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the help of the local CDCs. One FGD was organized
with one stakeholder. The number of participants for
each FGD was around 6–8.
The FGDs with the health care providers from the des-
ignated hospitals consisted of senior health administra-
tors responsible for public health, heads of TB or
infectious disease units, 2–3 chief consultants for TB
care, heads of nursing from TB units or wards, and one
senior and one junior nurse responsible for TB care. Is-
sues posed included the financing and expenditure of
TB care, provision of TB services, TB related health
workforce and their income levels, etc.
As for FGDs with patients, inclusion criteria were pa-
tients with previous TB treatment experience who could
clearly communicate their thoughts. Sex, age group, geo-
graphic location of residence, and socio-economic status
were considered. Both new and relapsed TB patients
were included in the group. Questions regarding their
use of and experiences with health care, expenses and
reimbursement related to TB care, and their subjective
feelings about their financial burden and the usefulness
of health insurance were asked.
A total of 12 FGDs were conducted by university fac-
ulty members. All FGDs were recorded under the per-
mission of participants. In addition, health insurance
policy documents related to the payment and reimburse-
ment of TB treatment as well as provider payment
methods were gathered from the study sites.
Definitions
In our study, total medical expenditure was composed of
the actual amount received as reimbursement and any
OOP payments. OOP payments were comprised of the
expenses below the deductible, the expenses above the
deductible which were co-paid by patients and the non-
reimbursable amount which were beyond the NCMS
benefit packages.
There were two major indicators to empirically measure
the reimbursement level: the effective reimbursement rate
and the non-reimbursable expenses rate. The effective re-
imbursement rate was the actual amount received as re-
imbursement divided by the total medical expenditure
[23]. The non-reimbursable expenses rate was the non-
reimbursable amount that were beyond the NCMS benefit
packages divided by the total medical expenditure.
The definitions mentioned above are consistent with
those used by the National Health and Family Planning
Commission in China.
It is widely known that there is no commonly accepted
criterion for defining CHE [24]. The criteria varies from
10 % of income [25, 26], 10 % of household consump-
tion [27], to 40 % of disposable income [28, 29]. In this
paper we regarded OOP health expenditures in excess of
10 % of annual family income as potentially catastrophic.
Analysis of the financial burden alleviation under the
NCMS and the extent to which this resulted in cata-
strophic expenditure before and after receiving the
NCMS reimbursement was also accomplished by coun-
terfactual analysis. The state of the households after re-
ceiving reimbursement from the NCMS was factual; the
state before households received reimbursement (as if
they were not covered by the NCMS) was regarded as a
counterfactual situation [30].
Two indicators were adapted: incidence and average
gap of CHE. We hypothesized that health demand of TB
patients would remain the same; then we proceeded to
compare the incidence and average gap of CHE due to
TB before and after the NCMS reimbursement. The in-
cidence of CHE describes the frequency of households
in six counties with health care costs as a share of total
expenditure exceeding the chosen threshold in propor-




CHEI refers to the incidence of CHE. And CI is the
catastrophe index. If a TB patient’s OOP payment as a
proportion of their annual income is ≥10 %, then CI = 1;
otherwise CI = 0. N is the total number of TB patients in
the sample.
Average gap of CHE captures the severity of CHE. It
describes how much a TB patient’s medical expenditure
(as a percentage of their annual income) is in excess of





AG refers to the average gap of CHE. And P is the
proportion of OOP cost as a percentage of the annual
income of TB patients who incur CHE. N is the total
number of TB patients in the sample.
The difference in CHE incidence and average gap be-
fore and after reimbursement reflects the impact of the
NCMS.
Equity before and after the NCMS reimbursement was
disaggregated by project sites and assessed by CI. Figure 1
presents the CI of CHE incidence rate. The CI is bounded
between −1 and 1. For a discrete living standards variable,







Where hi represents whether an individual suffers
from CHE (yes = 1, no = 0), μ is its mean, and ri = i/N is
the fractional rank of income, ranging from 0 to 1. For
one individual ranked i, r_i = (i-0.5)/N, in which N is the
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total number of individuals. In this study, the CI was
computed by the R programming language.
Data analysis
We used SPSS 17.0 to conduct the quantitative data ana-
lyses. The main analysis focused on the expenditure and
reimbursement of TB related services. Chi-square tests
were employed to identify differences in effective reim-
bursement rates between two research cities, and differ-
ences in the CHE incidences before and after NCMS
reimbursement. P < 0.05 was considered to be statisti-
cally significant. Total expenses after diagnosis were ana-
lyzed to measure TB care reimbursement under the
NCMS. In order to assess impact of the NCMS on TB fi-
nancial burden alleviation, we used expenses throughout
the treatment.
The resulting qualitative data were analyzed using the-
matic framework analysis [31]. Two researchers inde-
pendently read through all transcripts and listed
recruiting viewpoints relevant to questions in the inter-
view guidelines. Codes were developed based on topic
guides and the categories that emerged from the tran-
scripts, and were applied to the data to identify themes.
All qualitative data were coded, sorted and classified in
terms of the analysis framework. Nvivo10 was used to
manage the data. Charting was used to identify common
or divergent perceptions and explanations were devel-
oped. Analysis was carried out in Chinese to keep infor-
mation consistent and the final results were translated
into English.
Documents concerning health insurance policies were
also classified and analyzed by region using thematic
framework analysis.
Quality assurance
All the data collection instruments, tools and procedures
developed for the study were tested in a pilot exercise in
one project city. Following this pilot exercise, a workshop
was held to discuss any problems that arose and to iden-
tify appropriate modifications as required. A logic check
of all the data collected was also undertaken to identify
data gaps, inaccuracies, and apparent incongruities and
inconsistencies.
The patient surveys were conducted by university
students from local cities and provinces. These students
were trained on interview skills and the contents of the
questionnaire. All transcripts were cross-checked by dif-
ferent persons, allowing the identification and correction
of any data entry errors.
The NCMS data from ZJ County were partly excluded
due to errors in logic and only data from 2012 were in-
cluded in the analysis.
Ethical approval
Ethical permission was obtained from the Institutional
Ethics Committee, Chinese Center for Disease Control
and Prevention, China.
Results
Demographics of TB patients
A total of 494 patients participated in the survey. There
was a nearly even distribution within the six selected
counties. The average age of the study sample was
54.69 years and about three-fourths of the sample were
male. Over half of the participants had a primary school
education or lower while 34.8 % completed secondary
school and 11.3 % completed high school or higher. At
58.7 %, a majority of the participants were
employed,30.8 % were retired, 0.1 % were retired but
reemployed, 3.6 % were out of work, and 5.1 % were dis-
abled. And the remaining were students or pre-school
children. The average annual household income was
22795 yuan. These 494 patients were divided into three
groups by household income. The average annual house-
hold incomes were 3552 yuan, 17429 yuan and 53560
Fig. 1 Consideration index of CHE incidence
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yuan in the lower, median and upper quartiles, respect-
ively (Table 1).
Institutional background: The NCMS program in YC
and HZ
Since the NCMS is decentralized and administered at
the county level [16], we used the county as the unit for
our analysis. From health insurance policy documents
and FDGs, we gathered that general outpatient service
and outpatient service reimbursement for selected cata-
strophic or chronic diseases existed in the NCMS out-
patient reimbursement schemes. General outpatient
service only reimburses medical fees for outpatients in
primary-level medical and health care institutions, for
example, village clinics and township health centers, at a
certain proportion [32]. TB patients who must seek
treatment in a county-level, TB designated hospital
cannot claim reimbursement for general outpatient
care. In 2009, the NCMS covered catastrophic or
chronic outpatient costs in two-thirds of counties in
China [33]. Outpatient service reimbursement for se-
lected catastrophic or chronic diseases compensates
large outpatient expenditures by establishing the cata-
strophic or chronic diseases pooling fund with separate
deductibles and reimbursement caps. YC and HZ also
developed different payment arrangements for out-
patient care for specific catastrophic or chronic disease
conditions, including TB. TB outpatient services can
be reimbursed from pooled funds. Table 2 presents the
reimbursement rules for TB outpatients under the
NCMS by area.
Reimbursement for TB inpatient services follows simi-
lar trends as other inpatient services in all the NCMS
schemes. Inpatient deductibles are generally higher if pa-
tients receive treatment at higher level hospitals [34];
hence, the reimbursement rates decrease as the patients
seek care at higher level hospitals. Table 3 shows the de-
ductible and reimbursement rates, which indicates that
the ceiling level for expense reimbursement ranges from
RMB 100,000 to 150,000 yuan.
TB care reimbursement under the NCMS
According to the NCMS database 1884 TB inpatients
were reimbursed from 2010 to 2012 in YC and HZ, as
shown in Table 4. The rates of non-reimbursable expenses
accounted for 8.9 and 9.0 % of total inpatient expenses in
YC and HZ, respectively. In addition, we divided OOP
payments and the effective reimbursement rates by year.
Given the reliability of data, only data in YD and WF were
included (Figs. 2 and 3). These figures show the increase
in effective reimbursement rates by year, while OOP pay-
ments showed no obvious decline.
Table 5 shows TB outpatient and inpatient care reim-
bursement under the NCMS in YC and HZ using the
TB patient database. The effective reimbursement rate
of TB inpatient care after diagnosis accounted for 51.9
and 45.9 % in YC and HZ, respectively. There was no
statistically significant difference in the effective
Table 1 Social-economic characteristics of TB patients (n = 494)
Category Subcategory Results
(% (n))
Gender Female 120 (24.30)
Male 374 (75.70)
Age Age (Mean (SD)) 54.69 (14.56)










Education Primary school and lower 266 (53.80)
Secondary school or at the same
level
172 (34.80)
High school and higher 56 (11.30)
Employment Salaried job, farming or
self-employment
290 (58.70)
The retired but reemployment 3 (0.06)
Unemployment 18 (3.60)
The retired 152 (30.80)
Disability 25 (5.10)
Student/pre-school children 6 (1.20)
Household
income
Low (lowest 25) 133 (26.90)
(Missing = 3) Middle (medium 50) 234 (47.40)
High (top 25) 124 (25.10)
Table 2 Reimbursement by the NCMS for TB outpatient care
in 2012
Reimbursement rate or quota Ceiling
YD Quota subsidy 200 yuan/year
ZJ Quota subsidy 45 yuan/month 540 yuan/year
WF 70 % of total annual expenditure 2000 yuan/year
CG Quota subsidy 800 yuan/year
MX 80 % of total annual expenditure 1800 yuan/year
ZB Quota subsidy New patient ,2000 yuan/year;
Relapse patient, 2500 yuan/year
Data resource: Author’s data are collected from reimbursement policies of the
NCMS offices
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reimbursement rate for inpatient services between YC
and HZ (P > 0.05).
From the FGDs with doctors in designated hospi-
tals, we found that TB inpatients were confronted
with repeated treatment. We then analyzed service
utilization of TB patients who were interviewed and
found that 44.13 % of these patients received in-
patient care. A majority of TB inpatients (92.13 %)
were hospitalized in county or higher level hospitals
for initial treatment after diagnosis. On the other
hand, 17.13 % sought medical care in municipal
hospitals, resulting in lower reimbursement rates. Pa-
tients’ repeated treatment and high hospitalization
rates were caused by individual and health facility
factors, according to the FGDs.
“TB patients receive low outpatient reimbursement
rates. They prefer to be hospitalized, because they can
claim higher reimbursement rates, and it is more
comfortable and effective from their point of view.
Some patients think, ‘At least I can get a general
check-up.’”(Doctors in hospitals, FGDs)
“(The subsidy for doctors is insufficient), we make
money by ourselves.” (TB doctors, FGDs)
“They (Doctors) have profit-seeking behavior.”
(TB patients, FGDs)
Total outpatient expenses were near 1500 yuan after
diagnosis in YC, and it was about 800 yuan in HZ (see
Table 5). Outpatient expenses were high in certain coun-
ties, particularly in ZJ. The reimbursement level for TB
outpatient care after diagnosis was very low. The effect-
ive reimbursement rate of TB outpatient care accounted
for 5.2 and 48.3 % in YC and HZ, respectively. There
were significant differences (P < 0.05) in effective reim-
bursement rate for outpatient treatment between YC
and HZ. TB patients reflected that the reimbursement
for TB outpatient care was limited effect.
As mentioned above, the NCMS covered a package of
catastrophic or chronic disease-related services and TB
was included in YC and HZ. But the reimbursement was
based on a quota or was limited to a certain insured
amount. TB outpatients had to pay all expenses above
the quota out of pocket. In YD and ZJ, the quota levels
for TB outpatient care were significantly lower than the
corresponding outpatient expenses and that in HZ,
resulting in lower reimbursement levels compared to
counties in HZ. Moreover, reimbursement packages for
TB outpatient care were less comprehensive than those
Table 3 Reimbursement by the NCMS for TB inpatient care in 2012
County Deductible (Yuan) Nominal reimbursement rate (%)
Township health centers County hospitals Municipal hospital Township health centers County hospitals Municipal hospital
YD 100 500 500 85 65 50–65
ZJ 100 300 300–500 85 75 50–65
WF 50 200 500 80 70 55–65
CG 100–150 300–450 400–600 85–90 70–75 60–70
MX 100–150 300–550 350–550 85–90 75–80 60–70
ZB 100–150 300–550 400–550 80–90 70–80 60–70
Data resource: Author’s data are collected from reimbursement policies of the NCMS offices
Table 4 TB inpatient care reimbursement under the NCMS in YC and HZ from 2010 to 2012






Mean Median Mean Median
YD 430 4522 3106 2397 1513 7.8 47.0
ZJ 242 6372 4734 3048 1972 13.3 52.2
WF 329 4818 3148 2078 1195 5.8 56.9
Total 1001 5067 3602 2450 1609 8.9 51.6
CG 231 3878 3276 1730 1437 16.9 55.4
MX 233 4767 3907 1651 1376 13.7 65.4
ZB 419 4595 4131 1462 1281 2.7 68.2
Total 883 4453 3862 1582 1358 9.0 64.5
Data resource: Author’s data are collected from the NCMS database
Note: In YC, the NCMS data for three years are comprehensive with one exception of ZJ where only data in 2012 are included in the analysis. Given quality of
data, data in MX and ZB in 2010 are excluded in the analysis
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for TB inpatient care. Outpatient reimbursement pack-
ages in most counties excluded many services covered
by inpatient reimbursement packages, including CT
scans, which further reduced the proportion of effective
outpatient reimbursement.
“The reimbursement for outpatient care was low, and
it had no effect. I only got reimbursed for 200 yuan. ”
(TB patients, FGDs)
Impact of the NCMS on TB Financial Burden Alleviation
According to the Pearson’s chi square tests, there was no
statistically significant difference in the CHE incidence
before and after the NCMS reimbursement (P > 0.05),
with the exception of MX (P = 0.035). Most catastrophic
patients remained catastrophic; however, the average gap
of CHE was reduced after TB patients were reimbursed
from the NCMS, indicating a slight decline in the sever-
ity of CHE. The variation in average gap (Table 6) sug-
gests that the reimbursement policies of the NCMS were
effective in reducing CHE, but the impact was modest.
The CI, our measure of equity, was negative for the
NCMS reimbursement in all counties, indicating that in
all cases CHE incidence rate was pro-poor. Poorer pa-
tients were particularly vulnerable, with high rates of
catastrophic spending. But the absolute values of the CI
for CHE incidence rate were all below 0.4, suggesting
that equity was relatively reasonable. After the NCMS
reimbursement, the harsh economic effects of TB on
poorer populations were even worse, with the exception
of YD.
Discussion
A review of studies that measured the economic costs of
diseases, including TB, showed that low coverage and
user charges led to high costs [35]. Pan HQ et al. inter-
viewed 316 patients diagnosed from January 2010 to
May 2011 who had already completed their anti-TB
treatment in a cross-sectional survey, and found that the
average per capita total OOP payment was 3024.0 yuan.
They pointed out that the economic burden on patients
was still heavy [36]. Long Q et al. found that low income
patients paid a total of US$ 149 to 724 (RMB 1241 to
5228) for medical costs for a treatment course [37]. In
2011, the participation rate of NCMS was over 97 %
[38]. A majority of TB patients in rural China can be
covered by the NCMS, but as a government-subsidized
rural health insurance, it mainly focuses on helping
cover catastrophic medical expenses [39]. Its impact on
the alleviation of the economic burden of TB remains to
be seen. By accessing the effective reimbursement rates
of the NCMS among TB patients, Wei X et al. found
that the NCMS has not relieved the financial burden of
TB-related medical costs; however, they focused on the
TB dispensary approach.
Overall, our study revealed a mixed picture in terms of
TB care reimbursement, and how the NCMS has influ-
enced the level of financial burden and equity of TB pa-
tients under the integrated approach. More specifically,
the study yielded four major findings.
We found that TB patients paid out of pocket for an-
cillary services, which were not covered by the NCMS
[40], and revealed that TB outpatient care reimburse-
ment remained inadequate. The quota subsidy for TB
outpatient care led to inadequate outpatient reimburse-
ment. Small TB outpatient expenditures may seem to be
insignificant, but the annual cumulative amount maybe
catastrophic. Yip and her colleagues pointed out that the
NCMS does not address a major cause of medical im-
poverishment: expensive outpatient services for chronic
conditions [41]. Disparities between inpatient and out-
patient reimbursement policies possibly led to the high
hospitalization rates for TB patients. The hospitalization
costs were significantly higher, resulting in financial bur-
den for TB patients. Thus, prevention of hospitalizations
are needed [39].
We also found that effective reimbursement rates were
far lower than the nominal reimbursement rates for in-
patient care. There were three possible explanations for
low reimbursement rates for TB inpatient care. First, TB
Fig. 2 OOP in YD and WF by year
Fig. 3 The effective reimbursement rate in YD and WF by year
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patients had to be hospitalized at medical institutions at
the county level or above. In our study, 92.13 % of pa-
tients were treated at county hospitals or higher, but re-
imbursement rules were typically less generous for TB
patients hospitalized in higher level facilities. Large de-
ductibles (ranging from 200 yuan to 500 yuan in YC and
300 yuan to 600 yuan in HZ) and high co-payments
(ranging from 30 to 50 % in YC and 20 to 40 % in HZ)
reduced the proportion of effective reimbursement. As a
result, patients had to pay more OOP. Second, TB reim-
bursement packages were not comprehensive and cer-
tain expenses were excluded, including liver protection
drugs. Take the medicine reimbursement list of Hubei
province as an example – only eleven anti-TB items
were included in the NCMS, including streptomycin,
isoniazid, rifampicin, ethambutol, sodium aminosalicy-
late, pyrazinamide, rifapentine and rifamycin. Third, doc-
tors in TB designated hospitals had strong financial
incentives for excessive treatment under fee-for-service
payment systems, including the use of second-line anti-
TB drugs which were expensive and not included in re-
imbursement schemes. For example, the rate of non-
reimbursable expenses accounted for 10.07 % of total
medical expenditure in two cities.
The effective reimbursement rate for TB inpatient care
has increased over the years, while the OOP payments
have not. It appears that most of the reimbursement
from the NCMS was offset by the growth of medical ex-
penses [33], which was consistent with the analysis by
Wagstaff et al. who found that the NCMS did not reduce
OOP payments per outpatient visit or inpatient spell
[22]. Financial burden experienced by TB patients can
cause delays, low completion rates, poor adherence
and drug resistance, as well as CHE and impoverish-
ment [42, 43].
Reimbursement policy design for TB care led to differ-
ences in effective reimbursement rates between regions.
Higher nominal reimbursement rates and ceilings for TB
inpatient and outpatient care were offered in HZ when
compared with YC, as shown in Tables 2 and 3. TB pa-
tients in HZ encountered lower medical expenditures
and higher effective reimbursement rates, but the inci-
dence and severity of CHE remained higher when com-
pared with YC. This indicates that lower-income TB
patients in resource-poor settings bear a heavier finan-
cial burden, which is in line with other studies [44, 45].
In YC, the reimbursement level for TB outpatient
and inpatient care in ZJ was significantly lower than
that in YD and WF, and medical expenses for out-
patient and inpatient treatment were much higher.
Thus, TB patients in ZJ incurred the highest OOP
payments. Though the economic level of ZJ ranked in
Table 5 TB outpatient and inpatient care reimbursement after diagnosis under the NCMS in YC and HZ from 2010 to 2012
Area Outpatient Inpatient
Total Expenses (Yuan) OOP (Yuan) ERR (%) Total Expenses (Yuan) OOP (Yuan) ERR (%)
YD 1379 1307 5.2 9086 3947 56.6
ZJ 1942 1903 2.0 14732 7535 48.9
WF 1032 938 9.1 13247 6143 53.6
Total 1490 1413 5.2 13562 6530 51.9
CG 486 451 7.2 11425 7636 33.2
MX 751 584 22.2 7410 3766 49.2
ZB 1189 276 76.8 6542 2619 60.0
Total 832 430 48.3 8234 4454 45.9
Data resource: Author’s data are collected from TB patient database
Note: ERR refers to “the effective reimbursement rate”
Table 6 Incidence and average gap of CHE, and concentration index of CHE incidence rate before and after the NCMS
reimbursement by county
Counties Incidence Average gap Concentration index
Pre- Post- Reduction Pre- Post- Reduction Pre- Post- Reduction
YD 52.0 48.0 4.0 20.9 15.3 5.6 −0.34 −0.30 −0.04
ZJ 85.7 85.7 0.0 76.8 55.4 21.4 −0.12 −0.12 0.00
WF 70.0 56.7 13.3 40.0 18.6 21.4 −0.16 −0.32 0.16
CG 73.4 68.8 4.6 131.2 77.8 53.4 −0.16 −0.20 0.04
MX 87.3 70.9 16.4 199.1 108.5 90.7 −0.07 −0.24 0.17
ZB 80.3 72.1 8.2 198.3 126.2 72.1 −0.15 −0.17 0.02
Note: “Reduction” refers to reduction by the NCMS. It indicates the difference before and after the NCMS reimbursement
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the middle of the three sample counties in YC, the
incidence and severity of CHE remained the most ser-
ious. It shows that the main factors associated with
the incidence and severity of CHE are medical ex-
penditure and reimbursement level without consider-
ing other confounding factors.
TB patients paid a high proportion of medical care ex-
penditure through OOP payments after the NCMS re-
imbursement. Poor TB patients incurred high rates of
catastrophic spending due to inadequate reimbursement,
in line with other studies which have found that the oc-
currence and intensity of CHE was greater among poor
inpatients [10, 46, 47]; however, equity remained rela-
tively reasonable. A possible explanation may be that the
economically disadvantaged group constrained their es-
sential health demand, which in turn is another avenue
for further research.
We found the NCMS to be a protective factor in redu-
cing the severity of CHE in particular, which was con-
sistent with other studies [10, 18]. But the NCMS did
not reduce the CHE incidence, with the exception of
MX, due to inadequate outpatient and inpatient reim-
bursement levels, a finding that was in line with previous
studies [44], and only the severity of CHE was relieved.
The equity of CHE incidence has not improved after
the implementation of the NCMS. The effective reim-
bursement rate remains low under the NCMS, and since
the program targets reimbursement for overall benefi-
ciaries, equity improvement for TB patients is negatively
affected.
Establishing the National Medical Financial Assistance
Scheme (MFA) for the poor or disadvantaged may be ef-
fective in equity improvement. In 2003, the MFA was
implemented in rural areas to assist, among others, poor
and near-poor households facing high health care ex-
penses [22]. Although the MFA was established across
these six counties, the vast majority of TB patients could
not meet the requirements to obtain the assistance
services due to the strict admittance conditions.
Our study has its own limitations. First, since it was
based on counterfactual analysis, the level of medical ex-
penditures was assumed to be unchanged before and
after NCMS reimbursement, while behavioral responses
of patients and providers under reimbursement might
have changed, which would have led to an increase in
health expenditures. Thus, the impact of the NCMS on
the alleviation of economic burden might be overesti-
mated. This also reveals the fact that the NCMS has a
modest impact on reducing the financial burden experi-
enced by TB patients. Second, YC and HZ are two cities
with different social and economic levels. Different reim-
bursement policies were employed. Thus, in order to
eliminate confounding factors, comparisons were only
made within each city.
Conclusion
This study examined the impact of the NCMS on TB care
reimbursement and its effect on the financial burden of
TB patients. A number of conclusions can be drawn from
our findings. First, low reimbursement for TB outpatients
and inpatients due to low reimbursement quotas led to
heavy financial burdens on TB patients. Second, the effect-
ive reimbursement rates were lower than the reported
nominal reimbursement rates for inpatient care. We also
discovered a discrepancy between the lower effective re-
imbursement rates from the patient database and the
higher rates from medical expense records. Third, poorer
TB patients incurred higher rates of CHE, leaving lower
income patients in a more vulnerable position despite the
implementation of the NCMS. Fourth, the NCMS was
found to be a protective factor for CHE, but the impact
was modest. Furthermore, the equity of CHE did not im-
prove after the NCMS reimbursement.
Our findings are valuable for policymakers to develop
more effective interventions to relieve the financial bur-
den of TB patients enrolling in the NCMS. The major
policy implications from our study are twofold. First, in-
creasing the reimbursement level for TB outpatients and
reducing the variations in the reimbursement level
across counties are two important avenues to alleviate
the financial burden for TB patients and to increase the
equity of health insurance systems. Second, since TB pa-
tients need to spend significant amounts of money on
non-medical costs as well as on non-reimbursable med-
ical costs during the treatment process, relying on a
single policy tool such as health insurance coverage may
not completely solve the problem of high financial bur-
dens. A supplemental policy tool such as establishing an
MFA program may be necessary to improve equity.
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